Sarcopenic obesity: How do we treat it?

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 20, Issue 5, 2013, Pages 412-419

  Bouchonville, Matthew F ^a   Villareal, Dennis T ^b,c  

^a Division of Endocrinology   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

Author keywords

elderly; exercise; myostatin inhibitors; older adults; sarcopenic obesity; weight loss

Indexed keywords

CAPROMORELIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYOSTATIN; PRASTERONE; SOMATOMEDIN C; TESAMORELIN; TESTOSTERONE;

ANDROGEN THERAPY; BODY COMPOSITION; EXERCISE; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGONADISM; LEAN BODY WEIGHT; LIFESTYLE MODIFICATION; LONGEVITY; META ANALYSIS (TOPIC); MUSCLE ATROPHY; MUSCLE STRENGTH; MUSCULAR DYSTROPHY; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PHYSICAL PERFORMANCE; PRACTICE GUIDELINE; PROSTATE CANCER; PROTEIN INTAKE; PROTEIN SYNTHESIS; REVIEW; SARCOPENIA; SARCOPENIC OBESITY; SLEEP DISORDERED BREATHING; THERMOGENESIS; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; AGED; ANIMALS; COMBINED MODALITY THERAPY; HUMANS; LIFE STYLE; MYOSTATIN; OBESITY; RISK REDUCTION BEHAVIOR; SARCOPENIA; TESTOSTERONE;

EID: 84883655801     PISSN: 1752296X     EISSN: 17522978     Source Type: Journal    
DOI: 10.1097/01.med.0000433071.11466.7f     Document Type: Review

References (88)

1. Roubenoff R. Sarcopenic obesity: the confluence of two epidemics. Obes Res 2004; 12:887-888. (Pubitemid 41202387)
2. Villareal DT, Banks M, Siener C, et al. Physical frailty and body composition in obese elderly men and women. Obes Res 2004; 12:913-920. (Pubitemid 41202391)
3. Kim YS, Lee Y, Chung YS, et al. Prevalence of sarcopenia and sarcopenic obesity in the Korean population based on the Fourth Korean National Health and Nutritional Examination Surveys. J Gerontol A Biol Sci Med Sci 2012; 67:1107-1113.
4. Zizza CA, Herring A, Stevens J, Popkin BM. Obesity affects nursing-care facility admission among whites but not blacks. Obes Res 2002; 10:816-823. (Pubitemid 135687523)
5. Rantanen T, Harris T, Leveille SG, et al. Muscle strength and body mass index as long-term predictors of mortality in initially healthy men. J Gerontol A Biol Sci Med Sci 2000; 55:M168-M173. (Pubitemid 30243739)
6. Dominguez LJ, Barbagallo M. The cardiometabolic syndrome and sarcopenic obesity in older persons. J Cardiometab Syndr 2007; 2:183-189.
7. Rolland Y, Lauwers-Cances V, Cristini C, et al. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie de l'OSteoporose) Study. Am J Clin Nutr 2009; 89:1895-1900.
8. Baumgartner RN, Wayne SJ, Waters DL, et al. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res 2004; 12:1995-2004.
9. Stenholm S, Alley D, Bandinelli S, et al. The effect of obesity combined with low muscle strength on decline in mobility in older persons: results from the InCHIANTI study. Int J Obes (Lond) 2009; 33:635-644.
10. Stenholm S, Rantanen T, Heliovaara M, Koskinen S. The mediating role of C-reactive protein and handgrip strength between obesity and walking limitation. J Am Geriatr Soc 2008; 56:462-469. (Pubitemid 351327919)
11. Villareal DT, Apovian CM, Kushner RF, Klein S. Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, The Obesity Society. Am J Clin Nutr 2005; 82:923-934. (Pubitemid 43779747)
12. [also published in: Obes Res 2005; 13:1849-1863]
13. Milanovic Z, Pantelic S, Trajkovic N, et al. Age-related decrease in physical activity and functional fitness among elderly men and women. Clin Interv Aging 2013; 8:549-556.
14. Sarti S, Ruggiero E, Coin A, et al. Dietary intake and physical performance in healthy elderly women: a 3-year follow-up. Exp Gerontol 2013; 48:250-254.
15. Marcus RL, Addison O, Dibble LE, et al. Intramuscular adipose tissue, sarcopenia, and mobility function in older individuals. J Aging Res 2012; 2012:1-6.
16. Siegel MP, Wilbur T, Mathis M, et al. Impaired adaptability of in vivo mitochondrial energetics to acute oxidative insult in aged skeletal muscle. Mech Ageing Dev 2012; 133:620-628.
17. Proctor DN, Sinning WE, Walro JM, et al. Oxidative capacity of human muscle fiber types: effects of age and training status. J Appl Physiol 1995; 78:2033-2038.
18. Leger B, Derave W, De BK, et al. Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation. Rejuvenation Res 2008; 11:163-175B.
19. Lanza IR, Nair KS. Muscle mitochondrial changes with aging and exercise. Am J Clin Nutr 2009; 89:467S-471S.
20. Yeap BB, Paul Chubb SA, Lopez D, et al. Associations of insulin-like growth factor-I and its binding proteins and testosterone with frailty in older men. Clin Endocrinol (Oxf) 2013; 78:752-759.
21. EichholzerM, Barbir A, Basaria S, et al. Serum sex steroid hormones and frailty in older American men of the Third National Health and Nutrition Examination Survey (NHANES III). Aging Male 2012; 15:208-215.
22. Nass R. Growth hormone axis and aging. Endocrinol Metab Clin North Am 2013; 42:187-199.
23. Schrager MA, Metter EJ, Simonsick E, et al. Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol 2006; 102:919-925.
24. Waters DL, Ward AL, Villareal DT. Weight loss in obese adults 65years and older: a review of the controversy. Exp Gerontol 2013; doi.org/10.1016. [Epub ahead of print].
25. Villareal DT, Banks M, Sinacore DR, et al. Effect of weight loss and exercise on frailty in obese older adults. Arch Intern Med 2006; 166:860-866.
26. Wing RR, Hamman RF, Bray GA, et al. Achieving weight and activity goals among diabetes prevention program lifestyle participants. Obes Res 2004; 12:1426-1434. (Pubitemid 41137449)
27. Svetkey LP, Clark JM, Funk K, et al. Greater weight loss with increasing age in the weight loss maintenance trial. Obesity (Silver Spring) 2013; doi: 10.1002/oby.20506. [Epub ahead of print].
28. Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 2011; 364:1218-1229.
29. Brown M, Sinacore DR, Binder EF, Kohrt WM. Physical and performance measures for the identification of mild to moderate frailty. J Gerontol A Biol Sci Med Sci 2000; 55:M350-M355.
30. Villareal DT, Smith GI, Sinacore DR, et al. Regular multicomponent exercise increases physical fitness and muscle protein anabolism in frail, obese, older adults. Obesity (Silver Spring) 2011; 19:312-318.
31. Argiles JM, Orpi M, Busquets S, Lopez-Soriano FJ. Myostatin: more than just a regulator of muscle mass. Drug Discov Today 2012; 17:702-709.
32. McMahon G, Morse CI, Burden A, et al. Muscular adaptations and insulin-like growth factor-I (IGF-I) responses to resistance training are stretch-mediated. Muscle Nerve 2013; doi: 10.1002/mus.23884. [Epub ahead of print]
33. Fujita S, Rasmussen BB, Cadenas JG, et al. Aerobic exercise overcomes the age-related insulin resistance of muscle protein metabolism by improving endothelial function and Akt/mammalian target of rapamycin signaling. Diabetes 2007; 56:1615-1622. (Pubitemid 46842620)
34. Timmerman KL, Dhanani S, Glynn EL, et al. A moderate acute increase in physical activity enhances nutritive flow and the muscle protein anabolic response to mixed nutrient intake in older adults. Am J Clin Nutr 2012; 95:1403-1412.
35. Thornell LE. Sarcopenic obesity: satellite cells in the aging muscle. Curr Opin Clin Nutr Metab Care 2011; 14:22-27.
36. Lambert CP, Wright NR, Finck BN, Villareal DT. Exercise but not diet-induced weight loss decreases skeletal muscle inflammatory gene expression in frail obese elderly persons. J Appl Physiol 2008; 105:473-478.
37. Frimel TN, Sinacore DR, Villareal DT. Exercise attenuates the weight-loss-induced reduction in muscle mass in frail obese older adults. Med Sci Sports Exerc 2008; 40:1213-1219.
38. Anbalagan VP, Venkataraman V, Pradeepa R, et al. The prevalence of presarcopenia in Asian Indian individuals with and without type 2 diabetes. Diabetes Technol Ther 2013. [Epub ahead of print]
39. Hameed UA, Manzar D, Raza S, et al. Resistance training leads to clinically meaningful improvements in control of glycemia and muscular strength in untrained middle-aged patients with type 2 diabetes mellitus. N Am J Med Sci 2012; 4:336-343.
40. Dillon EL. Nutritionally essential amino acids and metabolic signaling in aging. Amino Acids 2012. [Epub ahead of print]
41. Volpi E, Campbell WW, Dwyer JT, et al. Is the optimal level of protein intake for older adults greater than the recommended dietary allowance? J Gerontol A Biol Sci Med Sci 2013; 68:677-681.
42. Volpi E, Mittendorfer B, Wolf SE, Wolfe RR. Oral amino acids stimulate muscle protein anabolism in the elderly despite higher first-pass splanchnic extraction. Am J Physiol 1999; 277:E513-E520. (Pubitemid 29458212)
43. Paddon-Jones D, Rasmussen BB. Dietary protein recommendations and the prevention of sarcopenia. Curr Opin Clin Nutr Metab Care 2009; 12:86-90.
44. Cuthbertson DJ, Babraj J, Smith K, et al. Anabolic signaling and protein synthesis in human skeletal muscle after dynamic shortening or lengthening exercise. Am J Physiol Endocrinol Metab 2006; 290:E731-E738.
45. Symons TB, Schutzler SE, Cocke TL, et al. Aging does not impair the anabolic response to a protein-rich meal. Am J Clin Nutr 2007; 86:451-456. (Pubitemid 47256931)
46. Volpi E, Mittendorfer B, Rasmussen BB, Wolfe RR. The response of muscle protein anabolism to combined hyperaminoacidemia and glucose-induced hyperinsulinemia is impaired in the elderly. J Clin Endocrinol Metab 2000; 85:4481-4490. (Pubitemid 32157622)
47. Leenders M, van Loon LJ. Leucine as a pharmaconutrient to prevent and treat sarcopenia and type 2 diabetes. Nutr Rev 2011; 69:675-689.
48. Rieu I, Balage M, Sornet C, et al. Leucine supplementation improves muscle protein synthesis in elderly men independently of hyperaminoacidaemia. J Physiol 2006; 575:305-315. (Pubitemid 44182713)
49. Schirwis E, Agbulut O, Vadrot N, et al. The beneficial effect of myostatin deficiency on maximal muscle force and power is attenuated with age. Exp Gerontol 2013; 48:183-190.
50. Zimmers TA, Davies MV, Koniaris LG, et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002; 296:1486-1488. (Pubitemid 34553097)
51. Yarasheski KE, Bhasin S, Sinha-Hikim I, et al. Serum myostatin- immunoreactive protein is increased in 60-92 year old women and men with muscle wasting. J Nutr Health Aging 2002; 6:343-348. (Pubitemid 36118984)
52. Grobet L, Martin LJ, Poncelet D, et al. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat Genet 1997; 17:71-74. (Pubitemid 27377534)
53. Schuelke M, Wagner KR, Stolz LE, et al. Myostatin mutation associated with gross muscle hypertrophy in a child. N Engl J Med 2004; 350:2682-2688. (Pubitemid 38788003)
54. Shan T, Liang X, Bi P, Kuang S. Myostatin knockout drives browning of white adipose tissue through activating the AMPK-PGC1alpha-Fndc5 pathway in muscle. FASEB J 2013; 27:1981-1989.
55. Wilkes JJ, Lloyd DJ, Gekakis N. Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance. Diabetes 2009; 58:1133-1143.
56. Amthor H, Macharia R, Navarrete R, et al. Lack of myostatin results in excessive muscle growth but impaired force generation. Proc Natl Acad Sci U S A 2007; 104:1835-1840. (Pubitemid 46239865)
57. Jackson MF, Luong D, Vang DD, et al. The aging myostatin null phenotype: reduced adiposity, cardiac hypertrophy, enhanced cardiac stress response, and sexual dimorphism. J Endocrinol 2012; 213:263-275.
58. Zhang L, Rajan V, Lin E, et al. Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease. FASEB J 2011; 25:1653-1663.
59. Wang K, Li Z, Li Y, et al. Muscle-specific transgenic expression of porcine myostatin propeptide enhances muscle growth in mice. Transgenic Res 2013. [Epub ahead of print]
60. Busquets S, Toledo M, Orpi M, et al. Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. J Cachexia Sarcopenia Muscle 2012; 3:37-43.
61. Chiu CS, Peekhaus N, Weber H, et al. Increased muscle force production and bone mineral density in ActRIIB-Fc-treated mature rodents. J Gerontol A Biol Sci Med Sci 2013. [Epub ahead of print]
62. Nakatani M, Kokubo M, Ohsawa Y, et al. Follistatin-derived peptide expression in muscle decreases adipose tissue mass and prevents hepatic steatosis. Am J Physiol Endocrinol Metab 2011; 300:E543-E553.
63. Zhang C, McFarlane C, Lokireddy S, et al. Inhibition of myostatin protects against diet-induced obesity by enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice. Diabetologia 2012; 55:183-193.
64. Wagner KR, Fleckenstein JL, Amato AA, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 2008; 63:561-571.
65. Krivickas LS, Walsh R, Amato AA. Single muscle fiber contractile properties in adults with muscular dystrophy treated with MYO-029. Muscle Nerve 2009; 39:3-9.
66. Giannesini B, Vilmen C, Amthor H, et al. Lack of myostatin impairs mechanical performance and ATP cost of contraction in exercising mouse gastrocnemius muscle in vivo. Am J Physiol Endocrinol Metab 2013; 305:E33-E40.
67. Gonzalez-Freire M, Rodriguez-Romo G, Santiago C, et al. The K153R variant in the myostatin gene and sarcopenia at the end of the human lifespan. Age (Dordr) 2010; 32:405-409.
68. Garatachea N, Pinos T, Camara Y, et al. Association of the K153R polymorphism in the myostatin gene and extreme longevity. Age (Dordr) 2013. [Epub ahead of print]
69. Santiago C, Ruiz JR, Rodriguez-Romo G, et al. The K153R polymorphism in the myostatin gene and muscle power phenotypes in young, nonathletic men. PLoS ONE 2011; 6:e16323.
70. Ferrell RE, Conte V, Lawrence EC, et al. Frequent sequence variation in the human myostatin (GDF8) gene as a marker for analysis of muscle-related phenotypes. Genomics 1999; 62:203-207. (Pubitemid 30053935)
71. Gruson D, Ginion A, Lause P, et al. Urotensin II and urocortin trigger the expression of myostatin, a negative regulator of cardiac growth, in cardiomyocytes. Peptides 2012; 33:351-353.
72. Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 2013; 10:245-284.
73. Giannoulis MG, Martin FC, Nair KS, et al. Hormone replacement therapy and physical function in healthy older men. Time to talk hormones? Endocr Rev 2012; 33:314-377.
74. Hildreth KL, Barry DW, Moreau KL, et al. Effects of testosterone and progressive resistance exercise in healthy, highly functioning older men with low-normal testosterone levels. J Clin Endocrinol Metab 2013; 98:1891-1900.
75. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:2647-2653. (Pubitemid 30641987)
76. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005; 90:678-688. (Pubitemid 40279179)
77. Urban RJ, Bodenburg YH, Gilkison C, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol 1995; 269:E820-E826. (Pubitemid 3005899)
78. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95:2536-2559.
79. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323:1-6. (Pubitemid 20209464)
80. Blackman MR, Sorkin JD, Munzer T, et al. Growth hormone and sex steroid administration in healthy aged women and men: a randomized controlled trial. J Am Med Assoc 2002; 288:2282-2292. (Pubitemid 35291758)
81. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007; 146:104-115. (Pubitemid 351640014)
82. White HK, Petrie CD, Landschulz W, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab 2009; 94:1198-1206.
83. Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab 2012; 97:4769-4779.
84. Villareal D, Holloszy JO. DHEA enhances effects of weight training on muscle mass and strength in elderly women and men. Am J Physiol Endocrinol Metab 2006; 291:E1003 L E1008.
85. Corona G, Rastrelli G, Giagulli VA, et al. Dehydroepiandrosterone supplementation in elderly men: a meta-analysis study of placebo controlled trials. J Clin Endocrin Metab 2013. [Epub ahead of print]
86. Schroeder ET, Zheng L, Yarasheski KE, et al. Treatment with oxandrolone and the durability of effects in older men. J Appl Physiol 2004; 96:1055-1062. (Pubitemid 38248683)
87. Schroeder ET, Zheng L, Ong MD, et al. Effects of androgen therapy on adipose tissue and metabolism in older men. J Clin Endocrinol Metab 2004; 89:4863-4872. (Pubitemid 39391420)
88. Der-Torossian H, Wysong A, Shadfar S, et al. Metabolic derangements in the gastrocnemius and the effect of Compound A therapy in a murine model of cancer cachexia. J Cachexia Sarcopenia Muscle 2013; 4:145-155.